クラミジア性尿道炎の治療オフロキサシンの臨床効果の検討

Abstract

クラミジア性尿道炎患者に対して1日600 mgのOfloxacinを14日間投与した.1) 26例全例でクラミジアは陰性化した.2)排尿痛, 尿道違和感など自覚症状は全例で消失した.3)初尿中多形核白血球(PMN), 尿道分泌物の量および尿道分泌物中PMNの改善率は薬剤投与14日目で各々15/22, 21/22, 20/21と良好であった.4)総合臨床効果は薬剤投与7日目, 14日目, 21日目で各々15/24, 18/22, 19/21であった.5)副作用は2例に認められが, 軽症であった.6)薬剤の投与期間は約2週間が適切と考えられた

Clinical effects of ofloxacin (OFLX) in the treatment of the patients with chlamydial urethritis was studied. OFLX was administered at a dose of 200 mg, three times daily (600 mg) for 14 days. In all of the 26 patients with chlamydial urethritis, C. trachomatis was eliminated in 7 to 14 days after the start of administration. The subjective clinical symptoms such as pain on urination and abnormal urethral feeling was disappeared in all cases within 7 days after the administration. The objective clinical symptoms, urethral discharge, polymorphonuclear leukocyte (PMNL) in urethral discharge and PMNL in first urine were improved in 94, 68, 91% respectively on 14 days after the administration. Overall clinical efficacy rate of OFLX on 7 days, 14 days and 21 days after the administration in this study was 63, 82, 91% respectively. Whereas subjective symptoms of side effects were noted in 2 patients (7.6%), any additional medical care was needed in none of them. Because of the marked improvement of clinical symptoms and the safety administration, OFLX could be the first regimen to be chosen for the treatment of the patients with chlamydial urethritis.